Abstract
No public abstract is available from the verified source records.
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
doaj
Confidence 92%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Role of local treatment to the prostate in patients with de novo low-volume metastatic hormone-sensitive prostate cancer receiving androgen receptor pathway inhibitors
10.1016/j.euros.2026.03.010 · 2026
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial
10.1016/s0140-6736(18)32486-3 · 2018
Efficacy and safety of prostate radiotherapy in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design
10.1016/s0140-6736(24)01865-8 · 2024
Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial
10.1200/jco.2017.75.3657 · 2018
Combination of androgen deprivation therapy with radical local therapy versus androgen deprivation therapy alone for newly diagnosed oligometastatic prostate cancer: a phase II randomized controlled trial
10.1016/j.euo.2022.06.001 · 2022
No additional external references are available.